T1	PROC 310 312	Rd
#1	AnnotatorNotes T1	C1881367; Lenalidomide-Dexamethasone Regimen; Therapeutic or Preventive Procedure
T2	CHEM 65 76	Daratumumab
#2	AnnotatorNotes T2	C2346801; daratumumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	CHEM 78 90	Lenalidomida
#3	AnnotatorNotes T3	C1144149; lenalidomide; Organic Chemical · Pharmacologic Substance
T4	CHEM 93 105	dexametasona
#4	AnnotatorNotes T4	C0011777; dexamethasone; Organic Chemical · Pharmacologic Substance
T5	CHEM 115 127	Lenalidomida
#5	AnnotatorNotes T5	C1144149; lenalidomide; Organic Chemical · Pharmacologic Substance
T6	CHEM 130 142	dexametasona
#6	AnnotatorNotes T6	C0011777; dexamethasone; Organic Chemical · Pharmacologic Substance
T7	DISO 158 174	mieloma múltiple
#7	AnnotatorNotes T7	C0026764; Multiple Myeloma; Neoplastic Process
T8	PROC 197 210	Ensayo fase 3
#8	AnnotatorNotes T8	C0282461; Phase 3 Clinical Trial; Research Activity
T9	CHEM 225 236	Daratumumab
#9	AnnotatorNotes T9	C2346801; daratumumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T10	CHEM 238 250	Lenalidomida
#10	AnnotatorNotes T10	C1144149; lenalidomide; Organic Chemical · Pharmacologic Substance
T11	CHEM 253 265	dexametasona
#11	AnnotatorNotes T11	C0011777; dexamethasone; Organic Chemical · Pharmacologic Substance
T12	CHEM 281 293	Lenalidomida
#12	AnnotatorNotes T12	C1144149; lenalidomide; Organic Chemical · Pharmacologic Substance
T13	CHEM 296 308	dexametasona
#13	AnnotatorNotes T13	C0011777; dexamethasone; Organic Chemical · Pharmacologic Substance
T14	DISO 329 356	mieloma múltiple en recaída
#14	AnnotatorNotes T14	C5577628; Relapsed/refractory multiple myeloma; Neoplastic Process
T15	DISO 394 410	Mieloma múltiple
#15	AnnotatorNotes T15	C0026764; Multiple Myeloma; Neoplastic Process
T16	DISO 458 474	mieloma múltiple
#16	AnnotatorNotes T16	C0026764; Multiple Myeloma; Neoplastic Process
T17	DISO 488 509	enfermedad mensurable
T18	PROC 557 568	tratamiento
#17	AnnotatorNotes T18	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T19	DISO 577 593	mieloma múltiple
#18	AnnotatorNotes T19	C0026764; Multiple Myeloma; Neoplastic Process
T20	CHEM 985 994	anti-CD38
#19	AnnotatorNotes T20	C4722395; Anti-CD38 Monoclonal Antibody; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T21	DISO 702 729	progresión de la enfermedad
#20	AnnotatorNotes T21	C0242656; Disease Progression; Pathologic Function
T22	PROC 942 950	terapias
#21	AnnotatorNotes T22	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T23	CHEM 952 963	daratumumab
#22	AnnotatorNotes T23	C2346801; daratumumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T24	PROC 972 994	tratamientos anti-CD38
T25	PROC 1013 1024	tratamiento
#23	AnnotatorNotes T25	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T26	DISO 1035 1042	mieloma
#24	AnnotatorNotes T26	C0026764; Multiple Myeloma; Neoplastic Process
T27	PROC 1084 1095	tratamiento
#25	AnnotatorNotes T27	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T28	DISO 1102 1112	enfermedad
#26	AnnotatorNotes T28	C0012634; Disease; Disease or Syndrome
T29	DISO 1132 1153	signos de resistencia
T30	CHEM 1174 1186	lenalidomida
#27	AnnotatorNotes T30	C1144149; lenalidomide; Organic Chemical · Pharmacologic Substance
T31	CHEM 1246 1258	lenalidomida
#28	AnnotatorNotes T31	C1144149; lenalidomide; Organic Chemical · Pharmacologic Substance
T32	DISO 1307 1329	acontecimiento adverso
#29	AnnotatorNotes T32	C0877248; Adverse event; Pathologic Function
T33	PROC 1349 1360	tratamiento
#30	AnnotatorNotes T33	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T34	CHEM 1372 1384	lenalidomida
#31	AnnotatorNotes T34	C1144149; lenalidomide; Organic Chemical · Pharmacologic Substance
T35	PROC 1478 1492	aleatorización
#32	AnnotatorNotes T35	C0034656; Randomization; Research Activity
T36	PROC 1403 1434	alotransplante de celulas madre
T37	ANAT 1540 1553	células madre
#33	AnnotatorNotes T37	C0038250; Stem cells; Cell
T38	PROC 1623 1650	trasplante de células madre
#34	AnnotatorNotes T38	C1504389; Stem cell transplant; Therapeutic or Preventive Procedure
T39	DISO 1663 1690	progresión de la enfermedad
#35	AnnotatorNotes T39	C0242656; Disease Progression; Pathologic Function
T40	DISO 1710 1727	neoplasia maligna
#36	AnnotatorNotes T40	C0006826; Malignant Neoplasms; Neoplastic Process
T41	DISO 1742 1758	mieloma múltiple
#37	AnnotatorNotes T41	C0026764; Multiple Myeloma; Neoplastic Process
T42	PROC 1799 1813	aleatorización
#38	AnnotatorNotes T42	C0034656; Randomization; Research Activity
T43	PROC 267 270	DRd
#39	AnnotatorNotes T43	C4526539; Daratumumab/Lenalidomide/Dexamethasone Regimen; Therapeutic or Preventive Procedure
T44	PROC 1210 1217	tratado
#40	AnnotatorNotes T44	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T45	PROC 654 661	régimen
#41	AnnotatorNotes T45	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T46	PROC 792 799	régimen
#42	AnnotatorNotes T46	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T47	DISO 1156 1168	intolerancia
#43	AnnotatorNotes T47	C0277585; Intolerance to drug; Pathologic Function
T48	PROC 1225 1232	régimen
#44	AnnotatorNotes T48	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T49	PROC 1523 1553	alotrasplante de células madre
T50	ANAT 1421 1434	celulas madre
#45	AnnotatorNotes T50	C0038250; Stem cells; Cell
T51	ANAT 1637 1650	células madre
#46	AnnotatorNotes T51	C0038250; Stem cells; Cell
T52	Date 12 16	2013
T53	LIVB 146 153	sujetos
#47	AnnotatorNotes T53	C0681850; Study Subject; Group
T54	LIVB 317 324	sujetos
#48	AnnotatorNotes T54	C0681850; Study Subject; Group
T56	Duration 1046 1061	las dos semanas
T57	Duration 1064 1079	cinco semividas
T58	LIVB 1117 1123	sujeto
#49	AnnotatorNotes T58	C0681850; Study Subject; Group
T63	Duration 1438 1452	las 12 semanas
T64	Duration 1763 1776	los tres años
T55	PROC 1281 1292	interrumpió
#50	AnnotatorNotes T55	C0850893; stop medication; Therapeutic or Preventive Procedure
T59	PROC 828 844	estado funcional
#51	AnnotatorNotes T59	C4525818; Clinical Performance Status; Health Care Activity | C3694602; functional status of patient; Therapeutic or Preventive Procedure
T60	Neg_cue 1729 1741	distinta del
A1	Status T33 History_of
A2	Status T34 History_of
A3	Status T44 History_of
A4	Status T48 History_of
A5	Status T31 History_of
A6	Status T36 History_of
A7	Status T49 History_of
A8	Status T40 History_of
A9	Assertion T41 Negated
A10	Status T22 History_of
A11	Status T23 History_of
A12	Status T24 History_of
A13	Status T25 History_of
A14	Status T45 History_of
A15	Status T18 History_of
#52	AnnotatorNotes T17	C1513041; Measurable Disease; Disease or Syndrome
#53	AnnotatorNotes T49	C2242529; Allogeneic Stem Cell Transplantation; Therapeutic or Preventive Procedure
#54	AnnotatorNotes T36	C2242529; Allogeneic Stem Cell Transplantation; Therapeutic or Preventive Procedure
A16	Status T20 History_of
T61	Neg_cue 1266 1274	excluirá
A17	Assertion T55 Negated
R1	Negation Arg1:T61 Arg2:T55	
A18	Assertion T32 Negated
R2	Negation Arg1:T61 Arg2:T32	
R3	Causes Arg1:T32 Arg2:T55	
R4	Causes Arg1:T33 Arg2:T32	
R5	Used_for Arg1:T34 Arg2:T33	
R6	Negation Arg1:T60 Arg2:T41	
R7	Combined_with Arg1:T2 Arg2:T3	
R8	Combined_with Arg1:T3 Arg2:T4	
R9	Combined_with Arg1:T5 Arg2:T6	
R10	Experiences Arg1:T53 Arg2:T2	
R11	Experiences Arg1:T53 Arg2:T5	
R12	Experiences Arg1:T53 Arg2:T7	
R13	Combined_with Arg1:T9 Arg2:T10	
R14	Combined_with Arg1:T10 Arg2:T11	
R15	Used_for Arg1:T9 Arg2:T43	
R16	Combined_with Arg1:T12 Arg2:T13	
R17	Used_for Arg1:T12 Arg2:T1	
R18	Experiences Arg1:T54 Arg2:T9	
R19	Experiences Arg1:T54 Arg2:T12	
R20	Experiences Arg1:T54 Arg2:T14	
T62	Observation 359 370	refractario
#55	AnnotatorNotes T62	C0438286; Absent response to treatment; Finding
R21	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T62	
T65	Quantifier_or_Qualifier 528 546	al menos una línea
R23	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T65	
T66	Observation 617 626	respuesta
#56	AnnotatorNotes T66	C1319171; Medication response; Finding
R24	Overlap Arg1:T18 Arg2:T66	
R25	Before Arg1:T19 Arg2:T66	
T67	Observation 628 630	RP
#57	AnnotatorNotes T67	C1521726; partial response; Finding
R26	Before Arg1:T19 Arg2:T67	
R27	Overlap Arg1:T18 Arg2:T67	
T68	Observation 617 626;633 638	respuesta mejor
R28	Before Arg1:T19 Arg2:T68	
R29	Overlap Arg1:T18 Arg2:T68	
R30	Overlap Arg1:T66 Arg2:T45	
R31	Overlap Arg1:T67 Arg2:T45	
T69	CONC 748 766	criterios del IMWG
#58	AnnotatorNotes T69	C5204711; International Myeloma Working Group Standard Response Criteria; Intellectual Product (?)
R32	Overlap Arg1:T21 Arg2:T46	
R33	After Arg1:T21 Arg2:T46	
T70	Quantifier_or_Qualifier 785 791	último
#59	AnnotatorNotes T70	C1517741; Last; Qualitative Concept
R34	Has_Quantifier_or_Qualifier Arg1:T46 Arg2:T70	
T71	CONC 849 853	ECOG
#60	AnnotatorNotes T71	C1520224; ECOG performance status; Intellectual Product
T72	Result_or_Value 857 865	0, 1 ó 2
R35	Has_Result_or_Value Arg1:T71 Arg2:T72	
R36	Used_for Arg1:T71 Arg2:T59	
R37	Used_for Arg1:T23 Arg2:T22	
R38	Used_for Arg1:T20 Arg2:T24	
R39	Overlap Arg1:T25 Arg2:T56	
R40	Has_Duration_or_Interval Arg1:T25 Arg2:T57	
R41	Overlap Arg1:T27 Arg2:T56	
R42	Has_Duration_or_Interval Arg1:T27 Arg2:T57	
R43	Experiences Arg1:T58 Arg2:T28	
R44	Experiences Arg1:T58 Arg2:T29	
R45	Overlap Arg1:T29 Arg2:T30	
R46	Causes Arg1:T30 Arg2:T47	
R47	Experiences Arg1:T58 Arg2:T47	
R49	Used_for Arg1:T31 Arg2:T44	
R50	Experiences Arg1:T58 Arg2:T44	
R51	Used_for Arg1:T31 Arg2:T48	
R52	Experiences Arg1:T58 Arg2:T48	
R53	Experiences Arg1:T58 Arg2:T32	
R54	Experiences Arg1:T58 Arg2:T33	
R55	Overlap Arg1:T36 Arg2:T63	
R56	Before Arg1:T36 Arg2:T35	
T73	Quantifier_or_Qualifier 1599 1607	previsto
#61	AnnotatorNotes T73	C1301732; Planned; Functional Concept
R57	Has_Quantifier_or_Qualifier Arg1:T38 Arg2:T73	
R58	Before Arg1:T38 Arg2:T39	
R59	Overlap Arg1:T40 Arg2:T64	
R60	Before Arg1:T40 Arg2:T42	
T74	Quantifier_or_Qualifier 640 653	al menos a un
R61	Has_Quantifier_or_Qualifier Arg1:T45 Arg2:T74	
R62	Overlap Arg1:T28 Arg2:T29	
R63	Overlap Arg1:T28 Arg2:T47	
R22	Overlap Arg1:T68 Arg2:T45	
#62	AnnotatorNotes T68	C0221607; Favorable response to treatment; Finding (?) | C0184784; Fair therapeutic response; Finding (?)
A19	Experiencer T58 Patient
A20	Experiencer T53 Patient
A21	Experiencer T54 Patient
A22	Status T38 Future
A23	Status T39 Future
